Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?

OBJECTIVE: To compare drug discontinuation risk between adalimumab (ADA) and etanercept (ETN) treatment among anti-tumor necrosis factor (anti-TNF)-naïve rheumatoid arthritis (RA) patients, in particular the influence of concomitant dose of methotrexate (MTX). METHODS: This retrospective nationwide...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Patient Prefer Adherence
Autors principals: Chen, Hsin-Hua, Chen, Der-Yuan, Chen, Yi-Ming, Tang, Chao-Hsiun
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4751906/
https://ncbi.nlm.nih.gov/pubmed/26917952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S94396
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars